LATAM MedTech Insights cover art

LATAM MedTech Insights

LATAM MedTech Insights

By: Ran Chen
Listen for free

About this listen

 Welcome to LATAM MedTech Insights, your essential guide to the booming medical technology and digital health sector across Latin America. Each episode, we dissect the key trends, investment opportunities, and regulatory news shaping the industry. Join us for in-depth interviews with the innovators, investors, and policymakers driving the future of healthcare from Mexico to Brazil.Copyright 2026 Ran Chen Biological Sciences Economics Science
Episodes
  • Pure Global: Brazil's Sudden SaMD Shockwave - The Unforeseen ANVISA Cybersecurity Mandate

    Pure Global: Brazil's Sudden SaMD Shockwave - The Unforeseen ANVISA Cybersecurity Mandate
    Apr 1 2026
    In this episode, we dissect a sudden and critical regulatory update from Brazil's ANVISA that was issued just last week. The new instruction imposes stringent cybersecurity and data handling requirements on all Software as a Medical Device (SaMD) and connected devices, catching many international manufacturers off guard and putting existing market approvals at risk. We explore the specific technical and documentation changes now required, from mandatory penetration testing to new data localization rules. This shift forces companies to rethink their entire compliance and operational strategy for Latin America's largest market. A case in point: A successful foreign manufacturer of remote patient monitoring tools, already established in Brazil, now faces an urgent compliance crisis. Their current registration is invalid, and they must rapidly re-engineer their product's data architecture and conduct a full cybersecurity audit to avoid being forced off the market. This is a costly and complex challenge that could halt their regional revenue stream. Key Takeaways: * What are the specific cybersecurity demands in ANVISA's new instruction for connected devices? * Do your existing products in Brazil now face an immediate compliance gap? * How will the new data localization rules impact your operational costs and IT infrastructure? * What is the new role and liability of local importers in ensuring device cybersecurity? * Are you prepared for a complete technical dossier re-submission for your software-based devices? * Why is Brazil making this sudden move, and which countries in LATAM are likely to follow? * How can this regulatory hurdle be turned into a competitive advantage? Struggling to keep up with unpredictable regulatory changes in LATAM? Pure Global offers end-to-end regulatory consulting, leveraging local expertise and advanced AI to streamline market access. Whether it's navigating Brazil's new cybersecurity rules or expanding into Mexico and Colombia, we act as your local representative to secure and maintain your market presence. Contact us for a strategic consultation at info@pureglobal.com or visit https://pureglobal.com/.
    Show More Show Less
    2 mins
  • Brazil's AI Gold Rush: Navigating the LGPD Data Maze with Pure Global

    Brazil's AI Gold Rush: Navigating the LGPD Data Maze with Pure Global
    Mar 31 2026
    Brazil's medical device authority has just unveiled a new framework for AI technologies, signaling a gold rush for innovators in the region. This new resolution promises a clearer path to market for cutting-edge software as a medical device, opening doors to Latin America's largest healthcare economy. But hidden within this opportunity is a critical challenge that could stop foreign companies in their tracks. The regulation mandates strict adherence to Brazil's General Data Protection Law (LGPD), a complex and demanding data privacy standard. This episode of LATAM MedTech Insights unpacks the new AI resolution, exposing the hidden compliance traps and what it really takes to succeed in this promising market. **A Case Study in Foresight:** An American AI diagnostic firm sees the news from Brazil and fast-tracks its expansion plan. Their device, already FDA-cleared, seems like a perfect fit. But their submission is quickly flagged. The reason? Their cloud data processing is handled on servers in the United States, a direct violation of the unwritten expectation of LGPD compliance for local data handling. Their market entry is now frozen, facing the unexpected and costly decision of whether to build new data infrastructure just for one market. **Key Takeaways:** * What is CFM Resolution 2,454/2026 and why is it more than just an approval pathway? * How does Brazil's LGPD law create a unique regulatory hurdle for AI medical devices? * Why might your global data strategy be incompatible with the Brazilian market? * What are the potential costs associated with data localization for MedTech companies? * How can a "privacy-by-design" approach give you a competitive advantage in Brazil? * What are the key differences between LGPD and GDPR that you must know? * Why is understanding the local regulatory culture just as important as reading the rules? At Pure Global, we specialize in navigating these complex regulatory landscapes. We offer end-to-end solutions, from developing your regulatory strategy to acting as your local representative in Brazil and over 30 other markets. Our combination of local expertise and advanced AI tools streamlines your path to market access. Don't let regulatory hurdles block your expansion. Contact us at info@pureglobal.com or visit https://pureglobal.com/ to learn more.
    Show More Show Less
    2 mins
  • Pure Global: Brazil's AI Rulebook - Cracking the New Medical AI Framework

    Pure Global: Brazil's AI Rulebook - Cracking the New Medical AI Framework
    Mar 30 2026
    In this episode, we dive into the landmark new resolution from Brazil’s Federal Council of Medicine (CFM) that creates a specific regulatory framework for Artificial Intelligence in medicine. This is a pivotal moment for digital health in Latin America, establishing new rules for physician oversight, data privacy, and the responsibilities of technology providers. We explore the immediate impact on MedTech and IVD manufacturers aiming to launch AI-powered solutions in the Brazilian market. This isn't just a guideline for doctors. it's a new set of requirements for the tools they use. We break down what this means for product design, technical documentation, and your overall market access strategy in Brazil. **Case Study:** A European MedTech firm has a powerful AI diagnostic software for radiology. They considered Brazil a prime market but were operating in a grey area. Now, the CFM resolution provides a path, but one with new obstacles. How must they adapt their AI's user interface to meet the "human oversight" mandate, and how can they prove their data processing is fully compliant with Brazil's stringent LGPD privacy law without a costly redesign? **Key Takeaways:** - How does the CFM's focus on physician liability change your product's risk management file? - Is your AI's algorithm explainable enough to meet the new transparency requirements? - What specific steps must you take to ensure your data practices are compliant with both the CFM resolution and Brazil's LGPD? - How will you need to modify your training and support materials for Brazilian medical professionals? - Does this new resolution require a separate clinical validation study for the Brazilian population? - How could this physician-centric framework in Brazil influence future AI regulations in other LATAM countries? At Pure Global, we offer end-to-end regulatory consulting solutions for Medical Technology and In-Vitro Diagnostic companies. We combine local expertise with advanced AI and data tools to streamline your global market access, including navigating complex new frameworks like Brazil's AI regulations. To get your product to market efficiently and correctly, contact us at info@pureglobal.com or visit https://pureglobal.com/.
    Show More Show Less
    2 mins
No reviews yet